Biotech Showcase™ 2016: Interview: Cenna puts its own spin on trusted amyloid beta target

February 11, 2016
Amyloid beta is a well-established target in Alzheimer’s disease, and yet there have been many failures in this development space. Cenna Biosciences Founder and CEO Nazneen Dewji explains to “The Pink Sheet” Senior Writer Emily Hayes why she thinks her company’s approach could succeed. Many approaches in the past have involved targeting enzymes that cleave amyloid beta out of its precursor, amyloid precursor protein (APP), resulting in a lot of off-target effects, Dewji explains. Also, drugs were given too late, when the damage was already done. In contrast, Cenna has developed technology that creates peptide drug candidates targeting APP. Cenna Biosciences is a spin-off of UCSD that has been funded to date by the National Institutes of Health. Dewji discusses early development plans that will put Cenna’s theories to the test. Find more videos and articles at http://www.partnering360.com/insight For more information on Biotech Showcase™, visit our webpage: http://www.ebdgroup.com/bts/index.php
Previous Video
Biotech Showcase™ 2016: Interview: Novaseek looks to boost R&D efficiency
Biotech Showcase™ 2016: Interview: Novaseek looks to boost R&D efficiency

Novaseek Research CEO Kate Torchilin outlines to “The Pink Sheet” senior writer Emily Hayes the key drivers...

Next Video
Biotech Showcase™ 2016: Interview: Enumeral aspires to take PD-1 inhibition to the next level
Biotech Showcase™ 2016: Interview: Enumeral aspires to take PD-1 inhibition to the next level

Enumeral CEO Arthur Tinkelenberg explains his company’s human-driven immune profiling platform and how it c...